



**Selvarani Elahi &
Chris Hopley**



CBD and controlled cannabinoids in consumer products

24 June 2021


Agenda



- **Background**
 - **The Need**
 - **Collaboration**
 - **Government Chemist CBD Project**
 1. **Guidance**
 2. **Wider collaboration & Training**
 3. **Method development**
 4. **International ring trial**
 5. **Impact**
-



U.S. CBD market, by distribution channel, 2014 - 2025 (USD Million)



Source: www.grandviewresearch.com

Legal Status



Home Office

- CBD as an isolated substance, in its pure form, would not be controlled under the MDA 1971 / MDR 2001
- Very difficult to isolate pure CBD
- High level of sensitivity required to accurately and consistently determine content
- If any controlled cannabinoids present - product would be controlled
- Intention to amend the MDR 2001 to permit CBD products containing no more than a defined percentage trace concentration of certain controlled cannabinoids
- Presumption has to be one of caution - a CBD containing product would be controlled under the MDA 1971 / MDR 2001 due to controlled cannabinoid content
- Home Office definition of an 'exempted product' according to Regulation 2 of the MDR 2001 – 3 limbs - 1mg 'threshold' per pack

Novel Food Status



- Hemp & related products not novel
 - Not the case for CBD extracts in food
 - Novel food status confirmed in January 2019
 - Retained European Law states they need to be authorised before placing on market
 - **Novel food application submitted before 31 March 2021**
 - Applicants need to include details of the toxicological studies conducted
 - 1 April 2021: only products with submitted applications (subsequently approved) & were on the market on 13 February 2020 will be allowed to remain on the market
 - **List CBD products linked to novel food applications (Eng & Wales)**
-



The GC Need

- **GC horizon scanning activities identified**
- **2020 – 2023 programme**
 - Assess the issues related to CBD in foods
 - Develop GC capability to determine CBD in foods
- **GC capability to discharge the statutory function of Referee Analyst in case of submission of referee samples**

Collaboration



FUNDED BY BEIS



Office for Product
Safety & Standards



Home Office





Government Chemist Project on CBD

1. Guidance



Government Chemist team publish a tutorial review of cannabinoids

This tutorial paper offers a review of the common names, abbreviations, regulation, psychoactivity and analytical methodology for the principle cannabinoids

From: [Government Chemist](#)

Published 19 May 2021



Government Chemist Guidance

Analytical Limits for Controlled Cannabinoids in Specified Products Containing Cannabidiol (CBD)

Michael Walker and Ian Axford

January 2021

2. Wider collaboration & Training



- **UKAS CBD Food Product approval Awareness Expert Group**
- **FSA-UKAS-LGC-Fera Group** to discuss the need for the production of a best practice measurement guide for CBD.
- **Joint Knowledge Transfer Framework for Food Standards and Safety**
 - FY 20/21 - Cannabidiol (CBD) in Food Supplements
 - FY 21/22 - Testing of CBD consumer products
- **App based MicroLearning Content Development**






3. Objectives of GC Laboratory Project



- Development of publicly available methods by January 2021:
 - Determination of CBD in Novel Foods / cosmetics
 - Determination of controlled cannabinoids in Novel Foods / cosmetics
- Transfer methods to UK regulatory (and other) labs via ring trial by March 2021
 - CBD & Controlled cannabinoids
 - Novel Foods & cosmetics

LC-MS/MS methods



Challenges



- Measurement of controlled drugs in presence of CBD
 - Some targets are very chemically similar to CBD
- Reproducibility (day to day, within day) of CBD measurements
 - Some examples of varying results between days
- Traceability of results
 - Good quality standards, high purity CBD
- 'Matrix' Interferences
 - Evidence of some formulations/ingredients affecting quantitative data
- Inconsistent Formulations
 - CBD containing products can be difficult to formulate, homogeneity issues



Cannabinoids of Interest



12 Controlled Plant Cannabinoids	
Trans-delta-9-tetrahydrocannabinol-C5	Δ9THC
Cis-delta-9-tetrahydrocannabinol-C5	Δ9THC
Delta-9-tetrahydrocannabinol-C4	Δ9THC-C4
Delta-9-tetrahydrocannabinol-C3 (Delta-9-tetrahydrocannabivarin)	THCV
Delta-9-tetrahydrocannabinol-C1	Δ9THC-C1
Delta-8-tetrahydrocannabinol	Δ8THC
Cannabinol-C1	CBN-C1
Cannabinol-C2	CBN-C2
Cannabinol-C3	CBV
Cannabinol-C4	CBN-C4
Cannabinol-C5	CBN
Cannabinol methyl ether-C5	CBNM-C5

- According to the literature:
 - most are present at low levels or not naturally occurring
 - Not readily available as standards
- Four cannabinoids highlighted in orange (Δ9THC, THCV, Δ8THC and CBN)
- THCA will be also be monitored (not controlled but readily converts into a THC)

Tetrahydrocannabinolic acid (THCA) as an isolated substance, in its pure form, would not be controlled under the MDA 1971 / MDR 2001. However, it is understood that THCA readily degrades both naturally, and with a catalyst or environmental change to THC which is a Schedule 1 controlled cannabinoid.



4. International ring trial

- **Samples – All commercially sourced**
 - CBD Hemp Food Oil
 - CBD Food Oil
 - CBD Cosmetic Oil
- **35 Participating Laboratories: 16 UK & 19 International**
- **12 March results deadline**
- **25 March – preliminary review**
- **April – statistical analysis**
- **June - final report published**



Home Office



Office for Product
Safety & Standards




Department for
Business, Energy
& Industrial Strategy

FUNDED BY BEIS




Results - Technologies



- Good range of technologies employed
- Approx 50/50 MS/spectroscopy


LGC-RT/20/A – Jacob Hooey CBD Oil 5%



LGC-RT/20/A – Jacob Hooey CBD Oil 5%




CBD a (fixed uncertainty of 15%)




- Same data plotted with a fixed 15% measurement uncertainty

Cannabinoid A (CBN)



Cannabinoid A (Delta 9 -THC)




Δ^9 -THC



- Using the LGC supplied method Δ^9 -THC cannot be confirmed in LGC-RT/20/A and LGC-RT/20/B as the MRM Transition 1/ Transition 2 values do not meet acceptance criteria
- LGC reported Δ^9 -THC as 'not confirmed' for both these samples
- These samples were later run on a longer and more complex method to calculate a value for Δ^9 -THC

Sample	Method	Δ^9 -THC Concentration ($\mu\text{g/ml}$)	Meets Acceptance Criteria
LGC-RT/20/A	LGC proprietary method	64.8	Yes
LGC-RT/20/A	LGC protocol method	94	No
LGC-RT/20/B	LGC proprietary method	1.8	Yes
LGC-RT/20/B	LGC protocol method	3.9	No


Cannabinoid A (Delta 9 -THC)




LGC-RT/20/A - Δ^9 -THC



Protocol method



LGC complex proprietary method





Ring Trial Conclusions

- CBD and controlled cannabinoid measurements are not straight forward
 - Interferences
 - Robustness
 - Product variance
- Methods developed by December 2020
- Cross government successful international ring trial executed within 8 weeks
- National and international capability for:
 - CBD in foods & cosmetics
 - Controlled cannabinoids (positive bias observed for $\Delta 9$ -THC but method fit for screening purposes)

5. MP wrote back to thank us for:

- Copying him in on the letter to the Chair
- Informing him of the role as Government Chemist and the ongoing work regarding CBD
- “....your valuable contributions on this subject”
- Invitation to present to the Home Office Advisory Committee for the Misuse of Drugs Working Group on CBD
- GC inputted into ACMD call for evidence for by providing international ring trial data for Δ^9 THC, THCV, Δ^8 THC, CBN & THCA



Hon

Pr
Ch
c/c
21
Lo
SV

By
AC

an
nat
for
THC
A.

a

id. In

be
id
l, in
cts.

ML
T LABORATORY
MEASUREMENT
POSTED AT LOC



Acknowledgements



Chris Hopley

Ian Axford

Michael Walker

Thierry Le Goff

Gary Bird

Steve Corless

Steven Dennis



Home Office



Office for Product
Safety & Standards



Food
Standards
Agency
food.gov.uk



Department for
Business, Energy
& Industrial Strategy

FUNDED BY BEIS

Tabatha Hambidge

Emily Whyte

Rebecca Nash

Abigail Fletcher

Julian Braybrook

Selvarani Elahi

